Using low concentrations of etoposide to induce DSBs primarily by the Top2α-mediated and replication-dependent mechanism is predicted to be a better strategy to maximize the preferential killing of highly proliferative cancer cells and minimize the Top2β-mediated side effects on oncogenic chromosomal translocations and post-mitotic cell survival. The gene discussed is TOP2A; the disease is cancer.